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Anping Cai, Guang Li, Jiyan Chen, Xida Li, Liwen Li* and Yingling ZhouAbstract
Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2) plays complex and adverse roles on
atherosclerosis. Current study was to investigate whether increased plasma Lp-PLA2 level is independently
associated with the severity of coronary artery diseases (CAD).
Methods: Totally 781 participants were enrolled and performed coronary angiography (CAG) to figure out the
number of coronary artery stenosis. According to clinical presentation, electrocardiography, cardiac biomarker, and
CAG result, participants were divided into control (excluded CAD), stable angina (SA), unstable angina (UA) and
acute myocardial infarction (AMI) groups. Baseline characteristics were recorded. Statistical analyses were performed
to evaluate the relationship between Lp-PLA2 level and CAD severity.
Results: Plasma levels of Lp-PLA2 in control, SA, UA and AMI groups were 7.38(3.33-9.26) μg/L, 5.94(2.89-8.55) μg/L,
8.56(5.34-11.95) μg/L and 8.68(5.56-13.27) μg/L respectively (P < 0.001). After adjusted for age, gender, smoking,
diabetes mellitus, hypertension, low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol
(HDL-C), apoprotein A (apoA) and statins, Lp-PLA2 level was still independently associated with CAD severity, with
odd ratio (OR) of 1.055 (AMI group versus control group, 95% confidence interval (CI) 1.021-1.090, P < 0.05).
Additionally, the relationship between Lp-PLA2 level and the number of stenosis coronary artery was also assessed.
Lp-PLA2 levels in control, single-vessel, and multiple-vessels stenosis groups were 7.38(3.33-9.26) μg/L, 7.80
(4.05-10.76) μg/L and 8.29(5.18-11.76) μg/L respectively (P for trend < 0.001). After adjusted for age, gender, smoking,
diabetes mellitus, hypertension, LDL-C and HDL-C, apoA and statins, Lp-PLA2 level remained independently
associated with the number of coronary artery stenosis, with OR of 1.053 (multiple-vessels stenosis group versus
control group, 95% CI 1.025-1.069, P < 0.05).
Conclusion: Increased Lp-PLA2 level is independently associated with CAD severity, and Lp-PLA2 level may be used
to discriminate those who are at increased risk of cardiovascular events.
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Atherosclerotic cardiovascular disease (ASCVD) is still the
leading cause of morbidity and mortality worldwide despite
great advances on diagnosis and treatment have been
achieved in the past decades [1]. Knowingly, inflammation
plays critical and continuous roles on the initiation and
progression of atherosclerosis and ASCVD [2,3], and in-
creased serum level of inflammatory biomarker such as
high sensitivity C-reactive protein (Hs-CRP) has been rec-
ognized as an important predictor for cardiovascular dis-
eases risk [4,5].
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is
an enzyme excreting predominantly from atherosclerotic
plaques by macrophages and neutrophils and then circulat-
ing in blood stream [6]. Previously, clinical epidemiological
studies showed that increased plasma level of Lp-PLA2 was
associated with increased risk of cardiovascular events such
as myocardial infarction and ischemic stroke [7-9], and Lp-
PLA2 inhibitors could significantly reduce the incident of
cardiovascular events as compared to placebo treatment
[10,11]. Data from basic experiments further supported
clinical findings [12-14]. For example, in animal model of
hyperlipidemia and hyperglycemia, as compared to placebo
treatment, Lp-PLA2 inhibitor reduced macrophage accu-
mulation, diminished necrotic lipid-core volume and thick-
ened fibrous cap of coronary atherosclerotic plaque [14].
Therefore, Lp-PLA2 has been incorporated into cardiovas-
cular diseases risk assessment algorithm [15]. Nevertheless,
despite striking and encouraging findings from previous
studies, two recent large randomized, controlled and pro-
spective clinical trials showed that darapladib treatment, a
selective Lp-PLA2 antagonist, resulted in no better im-
provement of clinical outcomes in patients with stable or
unstable coronary artery diseases (CAD) [16,17].
In light of the conflicting findings of previous studies, we
conducted a cross-sectional and observational clinical study
to investigate whether increased plasma level of Lp-PLA2 is
independently associated with the severity of CAD, and we
believe that the clinical implication of our study would add,
if any, valuable information to address whether Lp-PLA2
could be used to predict CAD risk in the future.
Methods
Studied subjects and protocols
Studied subjects were enrolled from January of 2013 to
April of 2014 after informed consent was obtained, and
our current study was approved by the Ethical Committee
of Guangdong General Hospital. Coronary angiography
was performed to figure out the number of coronary ar-
tery stenosis in terms of single or multiple vessels stenosis
(≥50% stenosis). Those without significant coronary artery
stenosis (<50% stenosis) were defined as control group.
Clinical presentations in terms of stable angina (SA), un-
stable angina (UA) or acute myocardial infarction (AMI)were diagnosed according to clinical manifestation, elec-
trocardiography findings and cardiac biomarkers by two
experts of cardiology. Demographic characteristics includ-
ing age, gender, family history of ASCVD, smoking status,
hypertension and diabetes mellitus were recorded by ques-
tionnaire and were double-checked by two experts of car-
diology. Fasting venous blood at admission was drawn for
the assessment of fasting blood glucose (FBG), total chol-
esterol (TC), triglyceride (TG), low density lipoprotein-
cholesterol (LDL-C), high density lipoprotein-cholesterol
(HDL-C), apoprotein A (apoA), apoprotein B (apoB), lipo-
protein (a) (Lp(a)) and glycated hemoglobin (HbA1c).
Plasma level of Lp-PLA2 at admission was evaluated by
enzyme-linking immune-absorbent assay (ELISA, com-
mercially brought from Shanghai Yueyan Biological.
Technology Co.,Ltd , and the inter-assay variant is less
than 11% and intra-assay variant is less than 9%) and the
assay range was 1 μg/L to 20 μg/L. All performances were
conducted in accordance to manufacture’s instruction and
three independent experiments were performed in duplicate.
For the purpose of figuring out whether increased plasma
level of Lp-PLA2 was associated with the severity of CAD,
all participants were divided into different subgroups on the
basis of two major categories in terms of the severity of clin-
ical presentation (stable angina, unstable angina, or acute
myocardial infarction) and the number of stenosis coronary
artery (single or multiple vessels stenosis).
Studied endpoint
The primary endpoint of our current study was to evaluate
the correlation between plasma level of Lp-PLA2 and the
severity of CAD, including the severity of clinical presenta-
tion and the number of coronary artery stenosis.
Statistical analyses
Continuous data was presented as mean ± SD or median
(inter-quartile range) appropriately, and compared by the
Student’s t-test when data was normally distributed, other-
wise compared by the Wilcoxon rank-sum test. Categorical
data was presented as percentage and compared by χ2 test.
Univariate and multivariate regression analyses were per-
formed to evaluate the relationship between Lp-PLA2 value
and the severity of CAD. Statistical analyses were performed
by using SPSS software version 18.0 (SPSS, Inc., Chicago,
Illinois). A value of P < 0.05 was considered significant.
Results
Baseline characteristics of studied subjects
Totally 678 participants were angiographically diagnosed as
CAD and 103 were ruled out of CAD and data was shown
in Table 1. In comparison to the controls, participants with
documented CAD were with more traditional risk factors.
Briefly, participants with CAD were more elderly and with
more prevalent of smoking and hypertension. Serum Lp(a)
Table 1 Baseline characteristics of participants
Group Control SA UA AMI P
N 103 190 293 195
Age (years) 60.57 ± 9.57 62.77 ± 10.68 64.70 ± 10.83 61.79 ± 11.84 0.002
Male (%) 67(65.0) 154 (81.1) 225(76.8) 159(81.5) 0.006
Family history (%) 8(7.8) 12 (6.3) 12(4.1) 6(3.1) 0.216
Smoking (%) 25(24.3) 73 (38.4) 105(35.8) 87(44.6) 0.006
Hypertension (%) 67(65.0) 108 (56.8) 191(65.2) 103(52.8) 0.025
Diabetes mellitus (%) 24(23.3) 61 (32.1) 93(31.7) 60(30.8) 0.396
FBG (mmol/L)* 5.41 (3.78-13.64) 5.64 (5.06-6.94) 5.74(4.97-7.49) 5.85(4.92-8.22) 0.148
HbA1c (%) 6.33 ± 1.59 6.50 ± 1.37 6.44 ± 1.25 6.48 ± 1.38 0.727
Lp(a)(mmol/L)* 96.05 (27.06-158.56) 130.15 (66.79-293.25) 172.97(82.43-420.94) 176.97(101.09-289.26) < 0.001
TC(mmol/L) 4.54 ± 1.07 4.29 ± 1.01 4.41 ± 1.22 4.43 ± 1.08 0.316
TG(mmol/L) 1.74 ± 1.40 1.59 ± 0.97 1.60 ± 0.95 1.64 ± 1.13 0.792
LDL-C (mmol/L) 2.72 ± 0.89 2.57 ± 0.86 2.67 ± 0.98 2.79 ± 0.91 0.263
HDL-C (mmol/L) 1.08 ± 0.26 1.02 ± 0.27 1.00 ± 0.25 0.90 ± 0.17 < 0.001
apoA(mmol/L) 1.18 ± 0.24 1.14 ± 0.32 1.10 ± 0.25 0.98 ± 0.20 < 0.001
apoB(mmol/L) 0.81 ± 0.18 0.77 ± 0.19 0.80 ± 0.22 0.85 ± 0.28 0.071
Lp-PLA2 (μg/L)* 7.37 (2.34-15.78) 5.94(2.89-8.55) 8.56(5.34-11.95) 8.68(5.56-13.27) < 0.001
Denote: *indicated median and inter-quartile range, FBG = fasting blood glucose, HbA1c = glycated hemoglobin, Lp(a) = lipoprotein (a), TC = total cholesterol,
TG = triglyceride, LDL-C = low density lipoprotein-cholesterol, HDL-C = high density lipoprotein-cholesterol, apoA = apoprotein A, apoB = apoprotein B,
Lp-PLA2 = lipoprotein associated-phospholipase A2.
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were profoundly lower in participants with CAD as com-
pared to the controls, and importantly the changes of lipid
profiles were associated with the severity of CAD. Notably,
plasma level of Lp-PLA2 was gradually elevated in parallel
with the increased severity of CAD. There was no significant
difference among other variables between these groups.
Briefly, the percentages of participants underwent statins
treatment before enrollment in the control, SA, UA and
AMI groups were 36.8%, 34.6%, 41.5% and 40.9% (P = 0.031)
respectively, and in the control, single and multiple vessels
stenosis groups were 36.8%, 40.2% and 41.7% (P = 0.036).Relationship between Lp-PLA2 level and severity of clinical
presentation
Participants were divided into 4 groups in accordance to the
severity of clinical presentation. Plasma level of Lp-PLA2 in
the control (n = 103), SA (n = 190), UA (n = 293) and AMI
(n = 195) groups were 7.38(3.33-9.26) μg/L, 5.94(2.89-8.55)
μg/L, 8.56(5.34-11.95) μg/L and 8.68(5.56-13.27) μg/L re-
spectively (AMI group versus control group, P < 0.001).
After adjusted for age, gender, smoking, diabetes mellitus,
hypertension, Lp(a), LDL-C, HDL-C, apoA and statins, Lp-
PLA2 level was still independently associated with severity
of CAD, with odd ratio (OR) of 1.055 (AMI versus control
group, 95% confidence interval (CI) 1.021-1.090, P < 0.05).Relationship between Lp-PLA2 level and the number of
coronary artery stenosis
In light of angiography findings, participants were divided
into control, single, or multiple vessels stenosis groups. Lp-
PLA2 levels in the control (n = 103), single-vessel stenosis
(n = 193), and multiple-vessels stenosis (n = 485) groups
were 7.38(3.33-9.26) μg/L, 7.80(4.05-10.76) μg/L, and 8.29
(5.18-11.76) μg/L respectively (P for trend < 0.001). After
adjusted for age, gender, smoking, diabetes mellitus, hyper-
tension, Lp(a), LDL-C, HDL-C, apoA and statins, Lp-PLA2
level remained independently associated with the number
of coronary artery stenosis, with OR of 1.053 (multiple-ves-
sels stenosis group versus control group, 95% CI 1.025-
1.069, P < 0.05).Discussion
Owing to its unique effects on the initiation and progression
of atherosclerosis [18,19], Lp-PLA2 has been recognized as
a novel and promising biomarker for cardiovascular diseases
risk evaluation, and data from clinical and basic research
also showed that Lp-PLA2 decrease was beneficial for
retarding atherosclerosis progression and reducing cardio-
vascular events [10,20]. Nevertheless, results from two re-
cent clinical trials named STABILITY and SOLID-TIMI52
did not show cardiovascular benefits of darapladib therapy
in patients with stable or unstable CAD [16,17]. Consistent
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current study shows that in the real world population in-
creased plasma level of Lp-PLA2 is not only independently
associated with more vessels stenosis but also portends a
higher risk of cardiovascular events such as acute coronary
syndrome.
Lp-PLA2 is an enzyme predominantly excreted from ath-
erosclerotic plaques by inflammatory cells and circulates in
blood stream. Pathologically, Lp-PLA2 augments inflam-
mation and oxidation by means of degrading oxidized-LDL
into two potent pro-atherosclerotic and pro-thrombotic in-
termediates named lysophosphotidylcholine (Lyso-PC) and
oxidized non-esterified fatty acids (oxNEFAs), which subse-
quently results in endothelium dysfunction, foam cells for-
mation, necrotic lipid-core expansion and fibrous cap
thinning [21]. Therefore, it is reasonable to speculate that
increased plasma level of Lp-PLA2 may contribute coron-
ary artery stenosis progression and accelerate atheroscler-
otic plaque rupture. Data from current cross-sectional
study also supported this hypothesis. As compared to those
without significant coronary artery stenosis (control group),
plasma level of Lp-PLA2 was gradually and significantly in-
creased in single and multiple vessels stenosis groups. Pre-
viously, data from Shahar Lavi and colleagues also showed
that early coronary atherosclerosis in humans was charac-
terized by Lp-PLA2 production, and local coronary produc-
tion of Lyso-PC, the active product of Lp-PLA2, was
associated with endothelial dysfunction and atherogenesis
[22]. Therefore, it might be possible that the higher Lp-
PLA2 level the more severe of endothelial dysfunction and
atherosclerosis would be. Although our current study has
not tested the differences of endothelial function in each
group, accumulating evidence from basic and clinical
research might be compelling to demonstrate the positive
relationship between increased Lp-PLA2 level and the im-
pairment of endothelial function. Apart from endothelium-
associated mechanisms, Lyso-PC and oxNEFAs also play
important and complex roles on atherosclerotic plaques de-
velopment [23]. Pathologically, both Lyso-PC and oxNEFAs
are capable of up-regulating intra-cellular adhesion mole-
cules (ICAM) expression, enhancing inflammatory cells in-
filtration and accumulation, promoting foam cells
formation and expanding necrotic lipid-core [24]. Overall,
Lp-PLA2 per se and its product concomitantly initiate and
accelerate atherosclerotic plaque development.
Of note, serum level of Lp(a) was significantly higher in
the AMI group than that of the control group, while
HDL-C and apoA were profoundly lower, suggesting that
these dyslipidemia might be also associated with the CAD
severity. However, after adjustment for these lipid profiles,
Lp-PLA2 level remained independently associated with
CAD severity. With regard to the anti-inflammation, anti-
oxidation and endothelium-protective effects, one might
speculate that statins might be capable to ameliorate theadverse effects resulted from Lp-PLA2 elevation. None-
theless, data from previous studies showed the conflicting
outcomes of statins therapy on Lp-PLA2 elevation.
Present research showed no confounding effects of statins
therapy on the relationship between Lp-PLA2 level and
CAD severity.
On the second critical point, results from our study
supported the notion that increased plasma level of Lp-
PLA2 predicted a more unstable phenotype of coronary
artery plaques. Of note, plasma levels of Lp-PLA2 were
comparable in the control and stable angina groups
(7.38(3.33-9.26) μg/L and 5.94(2.89-8.55) μg/L, respect-
ively). Nonetheless, Lp-PLA2 levels were significantly el-
evated in the unstable angina and acute myocardial
infarction groups (8.56(5.34-11.95) μg/L and 8.68(5.56-
13.27) μg/L, respectively). This finding was consistent
with previous reports [14,25]. Data from Frank D.
Kolodgie et al. showed that Lp-PLA2 staining was more
intense in human prone-rupture coronary atheroma
than that with relatively stable plaque [25]. Histologic
and pathological results from basic research further sup-
ported clinical findings. The landmark research used hy-
percholesterolemic and diabetic swine showed that Lp-
PLA2 played continuous role on coronary atheroscler-
otic plaque development [14]. Darapladib treatment re-
sulted in a considerable decrease in necrotic core area
and reduced medial destruction, thereby resulting in
relatively stable phenotype of plaques, which indirectly
suggested that Lp-PLA2 promoting plaque instability. Of
note that plasma levels of Lp-PLA2 were significantly
higher in the UA and AMI groups than that of the con-
trol and SA groups. To our best knowledge, it might be
due to Lp-PLA continuously releasing from unstable
prone-rupture or ruptured plaque. Therefore, we consid-
ered that increasing Lp-PLA2 level might portend an
upcoming cardiovascular event such as acute coronary
syndrome.
Limitations
There were limitations of our current study. First of all,
unavoidable bias of cross-sectional study exists with re-
gard to evaluate the relationship between Lp-PLA2 level
and severity of CAD. Nonetheless, traditional risk factors
had already been extensively adjusted and previous
abundant evidence also supported the positive relation-
ship between increased Lp-PLA2 level and cardiovascu-
lar diseases risks. Secondly, the ELISA kit used in our
current study maybe not consistent with previous use
and the assay range was quite different from previous
studies. Therefore it should be cautious to interpret our
findings since the reference value of plasma level of Lp-
PLA in our study was not consistent with previous stud-
ies. Nevertheless, three independent experiments were
performed in duplicate, therefore we believed that the
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group was convincing. Last but not the least, previous
studies had shown the relationship between Lp-PLA2 level
and CAD severity and it appeared that our study provided
not much new information. However, with respect to the
conflicting results about Lp-PLA2 antagonist on cardio-
vascular outcomes, we considered that data from our
study might add more evidence regarding the adverse ef-
fects of Lp-PLA2 on ASCVD, future studies selecting ap-
propriate subjects was still deserved to conduct.
Conclusion
Results from our study once again show that in patients
with CAD, increased plasma level of Lp-PLA2 predicts an
unstable phenotype of coronary atherosclerotic plaque
and is also associated with more coronary artery stenosis.
Dynamic evaluation of Lp-PLA2 level may provide prog-
nostic value on cardiovascular diseases risk assessment.
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